All
RSSArticles
-
Variety of strategies needed to educate IRB members & chairs
Human research protection rules and regulations evolve and change, and it’s difficult for even the most experienced IRB members and chairs to keep up with them.
-
The doc who kicked the hornet’s nest: Is conflict of interest overkill stalling medical advances?
Lisa Rosenbaum, MD, a cardiologist at Brigham and Women’s Hospital in Boston, caused quite a stir earlier this year when she challenged medical orthodoxy in writing a three-part series on conflict of interest issues.
-
Research noncompliance is a problem of system failure
Every IRB and research organization should view research noncompliance as systems failures that need to be dealt with professionally, consistently, and transparently, according to an IRB expert.
-
Verbal consent and decision tree assist research community
As informed consent and IRB work evolve, new tools can help ease the transformation.
-
ANPRM Update
The U.S. Department of Health and Human Services published a Notice of Proposed Rulemaking at press time in the Office of the Federal Register.
-
AllTrials launches U.S. campaign, demands clinical trial data release
Originally founded in the UK, the AllTrials Campaign have brought their crusade for clinical trial transparency to the United States.
-
Two Drugs Better Than One for Pulmonary Arterial Hypertension
Among subjects with pulmonary arterial hypertension who are treatment naïve, initial combination therapy with tadalafil and ambrisentan is associated with significantly lower risk of clinical failure than initial monotherapy with either tadalafil or ambrisentan.
-
Role of Transthoracic Echo in Staph Bacteremia
In patients without community-acquired Staph bacteremia, a high-risk cardiac condition, or IV drug use, a negative transthoracic echo excluded infective endocarditis.
-
Echocardiographic Parameters Predict Outcome in Peripartum Cardiomyopathy
Poor baseline left ventricular ejection fraction, greater degree of left ventricular dilation, and black race predict poorer subsequent recovery with conventional therapy.
-
MATRIX Reloaded: Bivalirudin Fails to Best Heparin in ACS
Among patients with acute coronary syndromes referred for percutaneous intervention, bivalirudin did not lower rates of major adverse cardiovascular events or net adverse clinical outcomes as compared with unfractionated heparin.